Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks likely to meet or exceed Wall Street’s lofty expectations.
Xylem (XYL)
Consensus Price Target: $167.41 (20.8% implied return)
Formed through a spinoff, Xylem (NYSE: XYL) manufactures and services engineered products across a wide variety of applications primarily in the water sector.
Why Does XYL Stand Out?
- Annual revenue growth of 14.8% over the last two years was superb and indicates its market share increased during this cycle
- Offerings are difficult to replicate at scale and lead to a top-tier gross margin of 37.7%
- Earnings per share grew by 17.7% annually over the last five years, massively outpacing its peers
Xylem’s stock price of $138.60 implies a valuation ratio of 25.6x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free for active Edge members.
Verra Mobility (VRRM)
Consensus Price Target: $29.33 (31.3% implied return)
Aiming to wrap technology and data around a historically manual and paper-based industry, Verra Mobility (NYSE: VRRM) is a leading provider of smart mobility technology to address tolls and violations, title and registration services, as well as safety and traffic enforcement.
Why Could VRRM Be a Winner?
- Impressive 18.4% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Superior product capabilities and pricing power lead to a best-in-class gross margin of 61.8%
- Earnings growth has massively outpaced its peers over the last five years as its EPS has compounded at 20.4% annually
At $22.34 per share, Verra Mobility trades at 16.7x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free for active Edge members.
UnitedHealth (UNH)
Consensus Price Target: $392.24 (19.9% implied return)
With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE: UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care.
Why Do We Like UNH?
- Decent 11.5% annual revenue growth over the last five years beat most of its peers, showing customers find value in its products and services
- Dominant market position is represented by its $435.2 billion in revenue, which gives it negotiating power over membership pricing and reimbursement rates
- Industry-leading 20.4% return on capital demonstrates management’s skill in finding high-return investments
UnitedHealth is trading at $327.08 per share, or 19.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.
Stocks We Like Even More
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.
